Method for diagnosing drug eruption risk induced by antiepileptic drug based on single nucleotide polymorphism in 21.33 region of short arm of chromosome 6
AssigneeRiken
InventorsYusuke NAKAMURA, Michiaki KUBO, Taisei MUSHIRODA, Takeshi OZEKI
Life of this patent
Estimating the term…
Abstract
The genotype of a single nucleotide polymorphism (SNP) existing in the 21.33 region of the short arm of chromosome 6, such as an SNP at the HLA-A locus, is analyzed, and, based on the results, drug eruption risk induced by an antiepileptic drug is diagnosed.
Claims7
A method for diagnosing drug eruption risk induced by an antiepileptic drug, comprising:
- analyzing a single nucleotide polymorphism in the 21.33 region of the short arm of chromosome 6;
- and
- diagnosing drug eruption risk induced by an antiepileptic drug based on a result of said analysis.
A probe for diagnosing drug eruption risk induced by an antiepileptic drug, said probe having a sequence of (1) or (2) below:
- (1) a sequence of 10 or more nucleotides in a nucleotide sequence selected from SEQ ID NOs:
- 1 to 12, said sequence of 10 or more nucleotides comprising the nucleotide at nucleotide position 61, or a complementary sequence thereof;
- (2) a sequence of 10 or more nucleotides comprising a single nucleotide polymorphism showing linkage disequilibrium with HLA-A*3101, or a complementary sequence thereof.
A primer for diagnosing drug eruption risk induced by an antiepileptic drug, which primer can amplify a region of (1) or (2) below:
- (1) a region in a nucleotide sequence selected from SEQ ID NOs:
- 1 to 12, said region comprising the nucleotide at nucleotide position 61;
- (2) a region comprising a single nucleotide polymorphism showing linkage disequilibrium with HLA-A*3101.
Dependencies are inferred from the claim text.